Over the past 20 years, several generations of THERAKOS™ Photopheresis instruments have been developed and refined in accordance with our ongoing commitment to the field of immune therapy.
The object is always to improve and shorten the treatment experience while maximizing efficacy.
Our second generation THERAKOS™ UVAR XTS® Photopheresis System combines a medical device with a drug therapy. The XTS System utilizes a modular design that minimizes setup time, reduces waste, and is patient-focused—all without altering the science of the therapy or its effect on the patient.
It features:
The next generation, THERAKOS™ CELLEX® Photopheresis System incorporates the innovative and advanced technologies, providing a new level of patient-focused care.
A small number of the total body lymphocytes (<10%) are collected via leukopheresis within the instrument.
Extracorporeally, Methoxsalen Sterile Solution, a photoactive substance, is added to the lymphocyte-rich fraction and subsequently irradiated with ultraviolet light.
Irradiation with ultraviolet light photoactivates Methoxsalen Sterile Solution, which targets DNA. Methoxsalen Sterile Solution forms single and double-stranded cross-links in DNA, leading to apoptosis of treated cells. The treated cells are then reinfused into the patient.
Although less than 10% of all lymphocytes are treated, some patients achieve a complete improvement in symptoms.
Although the exact mechanism of action is not known, photopheresis may activate the immune-mediated response to modulate malignant T lymphocytes.
Click the videos for a more detailed explanation of how extracorporeal photopheresis works
Specially designed for medical professionals to use in their practice.
Sherry's Experience
The Caregiver's Perspective
The Long Journey
About THERAKOS™ Photopheresis Treatment
How THERAKOS™ Photopheresis Works
See top Opinion Leaders address FAQs about THERAKOS™ Photopheresis
Indications
Methoxsalen Sterile Solution is indicated for extracorporeal administration with the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.
Methoxsalen should be used only by physicians who have special training in the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis Systems. Methoxsalen is contraindicated in patients exhibiting idiosyncratic reactions to psoralen compounds, patients with a specific history of a light sensitive disease, or patients with aphakia.
THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate extracorporeal volume loss or shifts, or patients with coagulation disorders. See Important Safety Information for additional details.
